marketcaparena

Alterity Therapeutics Ltd

ATHE · Figures in Australian dollars

About Alterity Therapeutics

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

alteritytherapeutics.com ↗

Leadership

  • David Allen StamlerChief Executive Officer
  • Niven Abby Sarah MacnishChief Financial Officer
Employees
9
Business address
MELBOURNE
Fiscal year ends
June 30
Listed
Nasdaq · ATHE

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$3.50
−$0.45 (−11.39%)past year
Market cap
$63M
At close
Sep 28, 2026

Share price vs index

Alterity Therapeutics's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Alterity Therapeutics is ahead, orange while it is behind. The values at the end are each one's change over the range.

Income statement

Revenue, gross profit and net income

FY26
Full year
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Operating leverage

FY26
Full year
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

FY26
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Cash flow statement

FY25
Full year
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted

Capital allocation

FY26
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Balance sheet

Assets, liabilities and equity

Q4 26
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

War chest

Q4 26
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.